A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators

被引:30
|
作者
Zhang, Fanrong [1 ,2 ]
Huang, Minran [3 ]
Zhou, Huanhuan [1 ,4 ]
Chen, Kaiyan [1 ,4 ]
Jin, Jiaoyue [1 ,5 ]
Wu, Yingxue [1 ,5 ]
Ying, Lisha [1 ,5 ]
Ding, Xiaowen [1 ,2 ]
Su, Dan [1 ,5 ]
Zou, Dehong [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
[2] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Surg, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China
关键词
REACTIVE PROTEIN/ALBUMIN RATIO; TO-MONOCYTE RATIO; CELL LUNG-CANCER; FREE SURVIVAL; D-DIMER; FIBRINOGEN; INFLAMMATION; OUTCOMES; THERAPY; TAXANES;
D O I
10.1245/s10434-019-07655-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Triple-negative breast cancer (TNBC) patients who achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have better prognoses. Objective. This study aimed to develop an intuitive nomogram based on simple laboratory indexes to predict the pCR of standard NAC in TNBC patients. Methods. A total of 80 TNBC patients who received eight cycles of thrice-weekly standard NAC (anthracycline and cyclophosphamide followed by taxane) and subsequently underwent surgery in Zhejiang Cancer Hospital were retrospectively enrolled, and data on their pretreatment clinical features and multiple simple laboratory indexes were collected. The optimal cut-off values of the laboratory indexes were determined by the Youden index using receiver operating characteristic (ROC) curve analyses. Forward stepwise logistic regression (likelihood ratio) analysis was applied to identify predictive factors for a pCR of NAC. A nomogram was then developed according to the logistic model, and internally validated using the bootstrap resampling method. Results. pCR was achieved in 39 (48.8%) patients after NAC. Multivariate analysis identified four independent indicators: clinical tumor stage, lymphocyte to monocyte ratio, fibrinogen level, and D-dimer level. The nomogram established based on these factors showed its discriminatory ability, with an area under the curve (AUC) of 0.803 (95% confidence interval 0.706-0.899) and a bias-corrected AUC of 0.771. The calibration curve and Hosmer-Lemeshow test showed that the predictive ability of the nomogram was a good fit to actual observation. Conclusions. The nomogram proposed in the present study exhibited a sufficient discriminatory ability for predicting pCR of NAC in TNBC patients.
引用
收藏
页码:3912 / 3919
页数:8
相关论文
共 50 条
  • [41] Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
    Meyer, Braydon
    Clifton, Samuel
    Locke, Warwick
    Luu, Phuc-Loi
    Du, Qian
    Lam, Dilys
    Armstrong, Nicola J.
    Kumar, Beena
    Deng, Niantao
    Harvey, Kate
    Swarbrick, Alex
    Ganju, Vinod
    Clark, Susan J.
    Pidsley, Ruth
    Stirzaker, Clare
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [42] Basal Marker Reactivity in Triple Negative Breast Carcinomas Does Not Predict Pathologic Complete Response Following Neoadjuvant Chemotherapy
    Kraus, J. A.
    Beriwal, S.
    Dabbs, D. J.
    Bhargava, R.
    MODERN PATHOLOGY, 2011, 24 : 49A - 49A
  • [43] Basal Marker Reactivity in Triple Negative Breast Carcinomas Does Not Predict Pathologic Complete Response Following Neoadjuvant Chemotherapy
    Kraus, J. A.
    Beriwal, S.
    Dabbs, D. J.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2011, 91 : 49A - 49A
  • [44] Using machine learning approaches to predict response to neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Fisher, Timothy Byron
    Li, Hongxiao
    Ts, Rekha
    Krishnamurthy, Jayashree
    Bhattarai, Shristi
    Janssen, Emiel A. M.
    Kong, Jun
    Aneja, Ritu
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)
    Chang, H. R.
    Slamon, D.
    Gornbein, J. A.
    Chung, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Jung, Yoon Yang
    Hyun, Chang Lim
    Jin, Min-Sun
    Park, In Ae
    Chung, Yul Ri
    Shim, Bobae
    Lee, Kyu Ho
    Ryu, Han Suk
    JOURNAL OF BREAST CANCER, 2016, 19 (03) : 261 - 267
  • [47] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [48] Impact of Race on Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy and Chemotherapy Alone for Early-Stage Triple-Negative Breast Cancer
    Polidorio, Natalia
    Perry, Lauren M.
    Sevilimedu, Varadan
    Montagna, Giacomo
    Abuhadra, Nour
    Morrow, Monica
    Downs-Canner, Stephanie
    Plitas, George
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S10 - S10
  • [49] Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio are not predictive of Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
    de Pinho, I. Soares
    Barroso, T.
    Trabulo, C.
    Campoa, E.
    Patel, V.
    Goncalves, L.
    Araujo, J.
    Monteiro, C.
    Ferreira, A.
    Machado, B.
    Damaso, S.
    Luz, P.
    de Sousa, R. Teixeira
    Costa, L.
    BREAST, 2023, 68 : S77 - S77
  • [50] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constatin, Guillaume
    Ilie, Alis
    Beltjens, Francoise
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Hennequin, Audrey
    Bertaut, Aurelie
    Coutant, Charles
    Causeret, Sylvain
    Ghozali, Niama
    Coudert, Bruno
    Arnould, Laurent
    FRONTIERS IN ONCOLOGY, 2024, 13